TOP 5 MOST VIEWED ARTICLES
RECENT COMMENTS
Article type: Grandround
Keywords: breast cancer, clinical trials, clinical research, MINDACT, TRANSBIG, clinical trials directive, .
This article has 0 comments
European research crisis: the cancer community must make its voice heard
The European Union aims to become “the most competitive and dynamic knowledge-based economy in the world”. Why then does it put so many obstacles in the way of research? And why is a world-beating breast cancer trial left short of funding and support?
» Marc Beishon
To read the complete article please click on the pdf icon
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.
ESO reserves the absolute right not to publish comments.
ESO reserves the absolute right not to publish comments.
CancerWorld invites you to visit:
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck and Novartis.






